Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The EMA at 20: CAT chair on where all the advanced therapies are, and Holoclar, the bright light of stem cell therapy

This article was originally published in Scrip

Executive Summary

Advanced therapy medicinal products (ATMPs) were never going to be easy products for regulators to deal with, which is why the European Medicines Agency's Committee for Advanced Therapy Medicinal Products (CAT) was set up in 2009. So far, the applications have not exactly flooded in, but this is likely to change over the next few years, says Dr Paula Salmikangas, chair of the CAT. She talks to Francesca Bruce about the pitfalls of developing an ATMP and why Europe's first stem cell therapy, Holoclar, was a beacon of light for the sector.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC028144

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel